BioCardia (BCDA) AI Stock Analysis

• Market Cap: $11.65M
• Dividend Yield: N/A
• Average Volume (3M): 63.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.04
• Revenue Growth: -99.36%
• EPS Growth: 63.06%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 5,177,890
• 10 Day Avg. Volume: 68,224
• 30 Day Avg. Volume: 63,547
• PEG Ratio: 0.22
• Price to Book (P/B): 26.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.50
• Enterprise Value/Market Cap: 4.97
• Enterprise Value/Revenue: 130.34
• Enterprise Value/Gross Profit: -271.69
• Enterprise Value/Ebitda: -1.96
• 1Y Price Target: $6.00
• Price Target Upside: 169.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 50 Neutral
• Price Target: $2.00 ▼(-10.31%Downside)

BioCardia's stock score is impacted primarily by its weak financial performance and concerning valuation metrics, which highlight ongoing profitability and stability challenges. Despite positive clinical and strategic developments, these financial weaknesses weigh heavily on the overall score.

Positive Factors

Financial Performance

Biocardia announced financial results with an EPS better than the analyst's estimate, indicating better-than-expected financial performance.

Financial Stability

The company has enough cash to fund ongoing operations through the first quarter of 2025, providing financial stability in the near term.

New Product

Morph DNA Introducer now commercially available, providing new revenue stream.

Negative Factors

Clinical Trial

DSMB determined that the study would not meet the primary Finkelstein Schoenfeld composite endpoint and recommended to pause enrollment.

Regulatory Challenges

PMDA willing to review CardiAMP HF data ahead of submission for approval in Japan.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia generates revenue through a combination of product sales, licensing agreements, and collaborations. The company primarily aims to commercialize its cell therapy candidates, such as CardiAMP and CardiALLO, upon successful completion of clinical trials and regulatory approvals. BioCardia also earns revenue from licensing its proprietary biotherapeutic delivery platform to other companies in the biopharmaceutical sector. Additionally, the company engages in partnerships and collaborations that provide research funding and milestone-based payments, further contributing to its revenue streams. These partnerships often align with BioCardia's strategic goals in advancing regenerative medicine solutions for cardiovascular diseases.

BioCardia Financial Statement Overview

Summary

BioCardia's financial performance is challenged by significant profitability issues, negative EBIT and net income margins, and high volatility in revenue. The balance sheet shows a weak equity position and high debt-to-equity ratio, indicating leverage risks. Cash flow remains negative, heavily relying on financing, which poses long-term financial health challenges.

Income Statement

BioCardia's income statement indicates significant challenges with profitability, as evidenced by consistently negative EBIT and net income margins. Revenue has been highly volatile, with a dramatic decrease over the years and a substantial dip in gross profit. This volatility, coupled with negative margins, suggests financial instability and a challenging path to profitability.

Balance Sheet

The balance sheet reveals a weak equity position with negative stockholders' equity in previous years, which has slightly improved to a positive figure recently. The debt-to-equity ratio is relatively high, indicating potential leverage risks. Despite an increase in cash and short-term investments, overall asset growth has been stagnant, raising concerns about long-term financial health.

Cash Flow

The cash flow statement shows consistently negative free cash flow, although there has been some improvement in operating cash flow relative to net income. High reliance on financing activities to manage cash flow needs highlights challenges in generating sufficient operating cash. This reliance on external financing can be risky if not managed carefully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-55.00K	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-213.00K	-4.33M	-7.25M	-10.55M	375.00K	141.00K
EBITDA	-5.68M	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-8.39M	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	2.17M	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	949.00K	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	850.00K	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	3.69M	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	-1.52M	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-8.12M	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-8.11M	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-6.00K	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	8.12M	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Positive. The current price of 2.23 is above the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.27, and below the 200-day MA of 2.36, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.15 is Neutral, neither overbought nor oversold. The STOCH value of 54.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥346.03B	10.53	-2.88%	2.63%	11.67%	-7.08%
BCDA	50 Neutral	$11.65M	―	-737.89%	―	-99.36%	63.06%
HCWB	49 Neutral	$10.74M	―	-9999.00%	―	-63.20%	15.71%
BRTX	48 Neutral	$12.38M	―	-117.16%	―	175.03%	55.34%
SNSE	40 Underperform	$10.56M	―	-64.18%	―	―	1.00%
CTXR	38 Underperform	$13.41M	―	-60.06%	―	―	8.99%
LPTX	31 Underperform	$11.70M	―	-202.81%	―	―	64.01%

BioCardia Corporate Events

BioCardia Secures Patent for Innovative Catheter System

On June 25, 2025, BioCardia announced the granting of US Patent No. 12,311,127 for its ‘Radial and Trans-endocardial Delivery Catheter’ by the United States Patent Office. This patent covers BioCardia’s minimally invasive catheter systems designed to deliver biologic therapies to the heart, enhancing treatment precision and safety. The Helix catheter system, integral to the company’s CardiAMP Cell Therapy program, is expected to significantly impact the treatment of ischemic cardiomyopathies and heart failure, potentially improving patient outcomes and facilitating the transition from development to commercialization.

The most recent analyst rating on (BCDA) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Advances Phase 3 CardiAMP HF II Trial

On May 6, 2025, BioCardia, Inc. announced that the University of Wisconsin in Madison has begun enrolling patients with ischemic heart failure in the ongoing pivotal Phase 3 CardiAMP HF II trial. This study is evaluating the CardiAMP cell therapy product for treating patients with ischemic heart failure with reduced ejection fraction and elevated cardiac stress markers. The trial aims to confirm the safety and efficacy of the therapy, which has shown promising results in improving survival and quality of life for heart failure patients. The study’s advancements include refined treatment dose definitions and improvements to the Helix system, potentially expanding patient eligibility and treatment effectiveness.

BioCardia Enrolls First Patient in Phase III Trial

On May 1, 2025, BioCardia announced the enrollment of the first patient in the Phase III CardiAMP HF II clinical trial at BayCare Morton Plant Hospital in Florida. This trial aims to confirm the safety and efficacy of its lead autologous cell therapy for heart failure, potentially impacting regulatory approvals and adoption. The trial builds on previous promising results, with advancements in patient eligibility and delivery systems, and is supported by the Maryland Stem Cell Research Fund and CMS reimbursement.

BioCardia’s CardiALLO Trial Advances After Safety Review

On April 15, 2025, BioCardia announced that the independent Data Safety Monitoring Board recommended the continuation of the CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial, following a positive review of the 30-day safety data. The trial, which showed no major adverse cardiac events or immune reactions, is set to progress with the enrollment of 39 participants in the United States. This development is significant for BioCardia’s MSC platform, potentially aiding discussions around funding and partnerships, and could lead to future pivotal trials and approvals in the USA and Japan.

BioCardia Clarifies Timing for CardiAMP-HF Results Call

On March 31, 2025, BioCardia, Inc. announced a clarification regarding the timing of its conference call to discuss the two-year CardiAMP-HF results. Initially reported to occur at 4:30pm PDT, the call was confirmed to take place at 4:30pm EDT. This announcement ensures stakeholders are informed of the correct timing to access the call, which is crucial for maintaining transparency and effective communication regarding the company’s clinical progress.

BioCardia Reports Positive Phase 3 CardiAMP-HF Results

On March 31, 2025, BioCardia announced the two-year outcomes of its Phase 3 CardiAMP-HF study, revealing that its autologous cell therapy significantly improved survival, reduced major adverse cardiac and cerebrovascular events, and enhanced quality of life in ischemic heart failure patients with reduced ejection fraction. The study, involving 115 patients across 18 centers in the U.S. and Canada, showed particularly strong results in patients with elevated NTproBNP biomarkers, indicating the therapy’s potential to address a significant unmet need in heart failure treatment and reduce healthcare costs.